Investigating the resource implications of hospital-administered myeloma therapies

Dr Andy Peniket, Clinical Director of Haematology at Oxford University Hospitals, discusses the results of his study into the resource implications of administering a myeloma treatment in hospital.

UK/NP/1806/0035ai - July 2018

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.